{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-24-000031","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2024-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.596627+00:00","generated_at":"2026-06-03T06:17:32.172373+00:00","sec_items":["5.02","5.07","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bio-Rad Life Science Group President Simon May resigns; James Barry appointed as successor","bullets":["Simon May resigns as EVP & President, Life Science Group, effective May 1, 2024, to pursue another opportunity.","James J. Barry promoted from SVP of Global Manufacturing to succeed May as EVP & President, Life Science Group, effective May 1, 2024.","Stockholders approved amendment to 2017 Incentive Award Plan, extending expiration to 2034 and allowing non-employee director participation.","Principal accounting officer role transferred to CFO Roop K. Lakkaraju, replacing interim Tania DeVilliers."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-24-000031","json":"https://secwatch.observer/filing/0000012208-24-000031.json","markdown":"https://secwatch.observer/filing/0000012208-24-000031.md","text":"https://secwatch.observer/filing/0000012208-24-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000031/0000012208-24-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000031/bio-20240422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T06:17:32.172373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5af55af0a1","claim":"Roop K. Lakkaraju was appointed as Executive Vice President and Chief Financial Officer (and principal financial officer) at BIO-RAD LABORATORIES, INC..","evidence_excerpt":"On April 26, 2024, the Company disclosed that Roop K. Lakkaraju, the Company’s Executive Vice President and Chief Financial Officer (and principal financial officer) will act as the Company’s principal accounting officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000031/0000012208-24-000031-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and Chief Financial Officer (and principal financial officer)"}]},{"claim_id":"bff7136a15","claim":"Simon May resigned as Executive Vice President and President, Life Science Group at BIO-RAD LABORATORIES, INC..","evidence_excerpt":"On April 22, 2024, Simon May, the Executive Vice President and President, Life Science Group, of Bio-Rad Laboratories, Inc. (the “Company”) and a named executive officer of the Company, notified the Company of his plans to resign from the Company to pursue another opportunity, effective as of May 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000031/0000012208-24-000031-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President and President, Life Science Group"}]},{"claim_id":"f28302fb34","claim":"James J. Barry was appointed as Executive Vice President and President, Life Science Group at BIO-RAD LABORATORIES, INC..","evidence_excerpt":"On April 24, 2024, James J. Barry, currently the Company’s Senior Vice President of Global Manufacturing, was appointed to the position of Executive Vice President and President, Life Science Group, effective May 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000031/0000012208-24-000031-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and President, Life Science Group"}]},{"claim_id":"aca9507ba797d118be6cfdb8e2f5dd213b8401b6","claim":"BIO-RAD LABORATORIES, INC. shareholders approved Election of Directors at the 2024-04-23 meeting.","evidence_excerpt":"1. Each of the nominated directors was elected and received the affirmative vote of a majority of the votes cast in the respective class of Common Stock, as follows:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000031/0000012208-24-000031-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-23"}]},{"claim_id":"e5d0c92c77bd446d6ffcdbab585951cab81a96a7","claim":"BIO-RAD LABORATORIES, INC. shareholders approved Ratification of KPMG LLP as independent auditors at the 2024-04-23 meeting.","evidence_excerpt":"2. The proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2024 was ratified and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000031/0000012208-24-000031-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-23"}]},{"claim_id":"f67bfe155970fab8888d60ab93ae208ca75da080","claim":"BIO-RAD LABORATORIES, INC. shareholders approved Approval of the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan, as amended at the 2024-04-23 meeting.","evidence_excerpt":"3. The proposal to approve the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan, as amended was approved and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000031/0000012208-24-000031-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-23"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}